Skip to content
Medical Health Aged Care

Significant investment in Federal Budget welcomed to support dementia

Dementia Australia 2 mins read

Dementia Australia welcomes the $2.2 billion investment in ongoing aged care reform announced tonight in the Federal Budget, including a range of dementia specific initiatives.

Dementia Australia Executive Director Services, Advocacy and Research Dr Kaele Stokes said tonight’s Federal Budget was an important step forward to improving the quality of care for people living with dementia, their families and carers.

“We welcome the continuing progress made by the Albanese Government in keeping dementia at the forefront by addressing key recommendations of the Royal Commission into Aged Care Quality and Safety,” Dr Stokes said.

The budget includes a raft of health and aged care measures that continue to build the capacity of acute and aged care services to deliver quality and appropriate care across community and residential settings as well as improving the coordination of care for people living with dementia who have more complex care needs.

“We also acknowledge the Government’s recognition of the need for a health system that can accommodate developments in biomarkers and disease-modifying therapies for dementia,” Dr Stokes said.

Dementia specific measures in the 2024-25 Federal Budget include:

  • $56.8 million for the expansion of the Commonwealth’s Acute to Residential Care Transition Service dementia program.
  • $30.4 million to states and territories to continue to deliver the Specialist Dementia Care Program.
  • $1.7 million for the Australian Dementia Network (ADNeT) for system readiness.
    Investment in understanding and supporting people impacted by less common forms of dementia.

“Given there are more than 421,000 people living with all forms of dementia in Australia we are committed to continuing to work with the Government to ensure the experiences of people impacted by dementia remain central to the design and roll out of these and future aged care reforms,” Dr Stokes said.

Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

-Ends-

Media contacts: Gabrielle Prabhu, Manager Media and Communications, 0403 177 754, gabrielle.prabhu@dementia.org.au

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au. 

Media

More from this category

  • Disability, Medical Health Aged Care
  • 20/12/2024
  • 17:36
Kuremara

Kuremara to Open a State-of-the-Art Activity Center in Milton, QLD, in January 2025

Kuremara, a trusted and leading NDIS-registered provider in Australia, is excited to announce the opening of its newest facility—a cutting-edge activity center in Milton,…

  • Contains:
  • Legal, Medical Health Aged Care
  • 20/12/2024
  • 17:29
JGA Saddler

BREAKING NEWS: Australian law firm takes on Johnson & Johnson for selling Australians ineffective medicine

Vision available: Lawyer and doctor VNR, editorial photos and radio grabs included can be found in this SharePoint File In-person lawyer interviews available by…

  • Contains:
  • Medical Health Aged Care
  • 20/12/2024
  • 12:01
NDARC/UNSW

ADHD drug shows promise for treating methamphetamine dependence, landmark Australian study shows

A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be repurposed as the first pharmacotherapy for people with methamphetamine dependence, according to a study published in Addiction. Results from the landmark ‘LiMA’ trial show that thepsychostimulant lisdexamfetamine can drastically reduce the need to use methamphetamine among those who are dependent on the illicit drug. Lead author and addiction medicine specialist Professor Nadine Ezard, who is Director of the National Centre for Clinical Research on Emerging Drugs (NCCRED), said the results were promising. "There is currently no pharmacotherapy approved for treating methamphetamine dependence," Professor Ezard said. “While further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.